Skip to Content
You are currently on the new version of our website. Access the old version .
  • Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
  • Article
  • Open Access

1 April 2014

fdg-pet in Two Cases of Neurofibromatosis Type 1 and Atypical Malignancies

,
,
,
,
,
,
,
and
1
Department of Pediatrics, Division of Pediatric Hematology and Oncology, Rainbow Babies and Children’s Hospital, Clevelan, OH 44106, USA
2
Division of Oncology and Center for Childhood Cancer Research, The Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
3
Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
*
Author to whom correspondence should be addressed.

Abstract

Patients with neurofibromatosis type 1 (NF1) are at increased risk for both benign and malignant tumours, and distinguishing the malignant potential of an individual tumour is a common clinical problem in these patients. Here, we review two cases of uncommon malignancies (Hodgkin lymphoma and mediastinal germ-cell tumour) in patients with nf1. Although 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET) has been used to differentiate benign neurofibromas from malignant peripheral nerve sheath tumours, FDG-PET characteristics for more rare tumours have been poorly described in children with NF1. Here, we report the role of PET imaging in clinical decision-making in each case. In NF1, FDG-PET might be useful in the clinical management of unusual tumour presentations and might help to provide information about the malignant potential of uncommon tumours.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.